Literature DB >> 9110930

Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket.

A Kikuchi1, T Sakaguchi, K Miwa, Y Takamiya, H G Rammensee, Y Kaneko, M Takiguchi.   

Abstract

The interaction between 9-mer peptides and HLA-B51 molecules was investigated by quantitative peptide binding assay using RMA-S cells expressing human beta2-microglobulin and HLA-B51 molecules. Of 147 chemically synthesized 9-mer peptides possessing two anchor residues corresponding to the motif of HLA-B*5101 binding self-peptides, 27 peptides bound to HLA-B*5101 molecules. Pro and Ala at position 2 as well as Ile at position 9 were confirmed to be main anchor residues, while Gly at position 2 as well as Val, Leu, and Met at position 9 were weak anchor residues for HLA-B*5101. The A-pocket is suspected to have a critical role in peptide binding to MHC class I molecules because this pocket corresponds to the N-terminus of peptides and has a strong hydrogen bond formed by conserved Tyr residues. Further analysis of peptide binding to HLA-B*5102 and B*5103 molecules showed that a single amino acid substitution of Tyr for His at residue 171(B*5102) and that of Gly for Trp at residue 167 (B*5103) has a minimum effect in HLA-B51-peptide binding. Since previous studies showed that some HLA-B51 alloreactive CTL clones failed to kill the cells expressing HLA-B*5102 or HLA-B*5103, these results imply that the structural change of the A-pocket among HLA-B51 subtypes causes a critical conformational change of the epitope for TCR recognition rather than influences the interaction between peptides and MHC class I molecules.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9110930     DOI: 10.1007/bf02440994

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  35 in total

1.  Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2.

Authors:  K C Parker; M A Bednarek; L K Hull; U Utz; B Cunningham; H J Zweerink; W E Biddison; J E Coligan
Journal:  J Immunol       Date:  1992-12-01       Impact factor: 5.422

2.  Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle.

Authors:  H C Guo; T S Jardetzky; T P Garrett; W S Lane; J L Strominger; D C Wiley
Journal:  Nature       Date:  1992-11-26       Impact factor: 49.962

3.  Identification of self peptides bound to purified HLA-B27.

Authors:  T S Jardetzky; W S Lane; R A Robinson; D R Madden; D C Wiley
Journal:  Nature       Date:  1991-09-26       Impact factor: 49.962

4.  Behcet's disease associated with HLA-B51 and DRw52 antigens in Italians.

Authors:  O R Baricordi; A Sensi; P Pivetti-Pezzi; S Perrone; A Balboni; G Catarinelli; F Filippi; L Melchiorri; A Moncada; P L Mattiuz
Journal:  Hum Immunol       Date:  1986-11       Impact factor: 2.850

5.  Different rates of HLA class I molecule assembly which are determined by amino acid sequence in the alpha 2 domain.

Authors:  A Hill; M Takiguchi; A McMichael
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

6.  The structure of HLA-B35 suggests that it is derived from HLA-Bw58 by two genetic mechanisms.

Authors:  T Ooba; H Hayashi; S Karaki; M Tanabe; K Kano; M Takiguchi
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

7.  Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules.

Authors:  K Falk; O Rötzschke; M Takiguchi; B Grahovac; V Gnau; S Stevanović; G Jung; H G Rammensee
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

8.  HLA-Bw51 and Behçet's disease.

Authors:  S Ohno; T Asanuma; S Sugiura; A Wakisaka; M Aizawa; K Itakura
Journal:  JAMA       Date:  1978-08-11       Impact factor: 56.272

9.  Discrimination of HLA-B5 crossreactive group antigens by human allospecific CTL clones.

Authors:  K Matsumoto; J Yamamoto; M Hiraiwa; K Kano; M Takiguchi
Journal:  Transplantation       Date:  1990-06       Impact factor: 4.939

10.  Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries.

Authors:  K Udaka; K H Wiesmüller; S Kienle; G Jung; P Walden
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more
  6 in total

1.  Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection.

Authors:  G W Nelson; R Kaslow; D L Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides.

Authors:  Daniel Gebreselassie; Hans Spiegel; Stanislav Vukmanovic
Journal:  Hum Immunol       Date:  2006-09-20       Impact factor: 2.850

3.  Role of strong anchor residues in the effective binding of 10-mer and 11-mer peptides to HLA-A*2402 molecules.

Authors:  M Ibe; Y I Moore; K Miwa; Y Kaneko; S Yokota; M Takiguchi
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

4.  A single amino-acid polymorphism in pocket A of HLA-A*6602 alters the auxiliary anchors compared with HLA-A*6601 ligands.

Authors:  Christina Bade-Doeding; Holger-Andreas Elsner; Britta Eiz-Vesper; Axel Seltsam; Ute Holtkamp; Rainer Blasczyk
Journal:  Immunogenetics       Date:  2004-04-30       Impact factor: 2.846

5.  Polymorphic sites away from the Bw4 epitope that affect interaction of Bw4+ HLA-B with KIR3DL1.

Authors:  Bharati Sanjanwala; Monia Draghi; Paul J Norman; Lisbeth A Guethlein; Peter Parham
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

6.  Identification of an Unconventional Subpeptidome Bound to the Behçet's Disease-associated HLA-B*51:01 that is Regulated by Endoplasmic Reticulum Aminopeptidase 1 (ERAP1).

Authors:  Liye Chen; Hui Shi; Danai Koftori; Takuya Sekine; Annalisa Nicastri; Nicola Ternette; Paul Bowness
Journal:  Mol Cell Proteomics       Date:  2020-03-11       Impact factor: 5.911

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.